VVL-TD-IL-27

VVL-TD-IL-27 is a genetically engineered oncolytic vaccinia virus armed with the gene for interleukin-27 (IL-27), designed for cancer immunotherapy, particularly for pancreatic cancer. By inserting the IL-27 gene under the control of the H5 promoter in the viral genome, the therapy delivers IL-27 directly to the tumor microenvironment upon viral infection. This approach enhances the immune-mediated antitumor effect through several mechanisms: increasing intratumoral viral replication and persistence, elevating CD8+ effector memory T cells, decreasing regulatory T cells and overall macrophage populations, promoting macrophage polarization to an M1 (antitumor) phenotype, and exerting potent anti-angiogenic (blood vessel-reducing) activities. The addition of IL-27 increases both adaptive and innate immune responses within tumors, supporting robust tumor clearance and long-term immunological memory. Preclinical murine studies have demonstrated superior efficacy of VVL-TD-IL-27 over non-cytokine-armed oncolytic viruses, with complete tumor remission and induction of long-term antitumor immunity. Clinical development for gastrointestinal malignancies, especially pancreatic cancer, is considered warranted[1].